Genetics Problems (Monohybrid) #5.21
Genetics Problems (Monohybrid) #5.21

By: MrGarrettbenjamin

Continue reading here:
Genetics Problems (Monohybrid) #5.21 - Video

Recommendation and review posted by Bethany Smith

Uno Lady- Yellow Mustard Submarine
Video recorded and edited by Carmen Navis. Yellow Mustard Submarine written and recorded by Uno Lady. From the 2009 tape release, I really like genetics but I #39;d rather have a good time. Video from Tower 2012 bus tour to Detroit, MI and the Flower Shop in Chicago, IL. http://www.unolady.com

By: TheUnoLady

See more here:
Uno Lady- Yellow Mustard Submarine - Video

Recommendation and review posted by Bethany Smith

Study Guide Genetics Mitosis Meiosis #5.25
Study Guide Genetics Mitosis Meiosis #5.25

By: MrGarrettbenjamin

Original post:
Study Guide Genetics Mitosis Meiosis #5.25 - Video

Recommendation and review posted by Bethany Smith

MaddFarmer Genetics Urkle Queen
Grown by ~H~

By: Dublin Skunkfiend

See more here:
MaddFarmer Genetics Urkle Queen - Video

Recommendation and review posted by Bethany Smith

Yoga Teacher Gets Double Mastectomy to Avoid Breast Cancer | Inner Visions, Outer Triumphs
http://www.stoneweardesigns.com. Yoga teacher, long-time yoga practitioner, mother, wife, former corporate employee, Emily Goble tested positive for both breast cancer and ovarian cancer genetics. Because her mother has struggled with eight different types of cancer over 25 years and Goble was 87% likely to get breast cancer and 90% for ovarian, she voluntarily opted for a double mastectomy and will soon be undergoing a voluntary hysterectomy. Wow. Check out the Inner Visions, Outer Triumphs video for more on her extraordinary journey. The article below focuses on Goble #39;s yoga teaching and the support her students offered her through the process. Read more at http://www.livestonewear.com

By: StonewearDesigns

Read the original post:
Yoga Teacher Gets Double Mastectomy to Avoid Breast Cancer | Inner Visions, Outer Triumphs - Video

Recommendation and review posted by Bethany Smith

Copy of MaddFarmer Genetics Urkle Queen
Grown by ~H~

By: Dublin Skunkfiend

View original post here:
Copy of MaddFarmer Genetics Urkle Queen - Video

Recommendation and review posted by Bethany Smith

Fallout 3 Awesome Adventures Part 1: Black Dad
I find out about the ways of genetics of birth and have fun doing it! Along with some physics and bad parenting skills so enjoy!

By: AwesomeMat64

Read the rest here:
Fallout 3 Awesome Adventures Part 1: Black Dad - Video

Recommendation and review posted by Bethany Smith

Apa itu Fastabiqul Khairat?
soundtrack : First Breath After Coma - Explosion In The Sky credit to seniors involved : Bro Firdaus ASIS 3rd year - Ecology Biodiversity Bro Hanif ASIS 3rd year - Microbiology Sis Andi Nur Hazirah ASIS 3rd year - Biohealth Sis Fatimah Zahra SEMPIS 1st year - Genetics Molecular Biology

By: KerabatAPIDS

Continue reading here:
Apa itu Fastabiqul Khairat? - Video

Recommendation and review posted by Bethany Smith

Christiana Care: Cancer Genetic Counseling
Knowing the risks for cancer in your family may help you to avoid cancer or to find it early, when it is most curable. The genetic risk assessment program at Christiana Care #39;s Helen F. Graham Cancer Center can help identify your risks for hereditary cancer based on family history and genetics, as well as additional personal and environmental factors.

By: ContentDelaware

See more here:
Christiana Care: Cancer Genetic Counseling - Video

Recommendation and review posted by Bethany Smith

Public release date: 13-Jan-2013 [ | E-mail | Share ]

Contact: Kathy Beal kbeal@acmg.net 301-238-4582 American College of Medical Genetics

Health, science and genetics reporters are invited to register now for the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, March 19-23, 2013 at the Phoenix Convention Center. From Genetic Testing to Whole Genome/Exome Sequencing, the focus of the ACMG Meeting is on the actual practice of genetics and genomics in healthcare today and in the future. The conference will showcase the latest breakthroughs in genetics research and its practical applications to medical practice and public health. The ACMG Annual Meeting attracts medical and scientific leaders from around the world who are working to apply research in genetics and the human genome to the diagnosis, management, treatment and prevention of genetic conditions and rare and common diseases.

From the cytogenomics of cancer to neurogenetics; from noninvasive prenatal diagnosis to whole genome analysis; and from medical reimbursement issues to next generation sequencing, reporters will hear about the latest research; have the opportunity to interact with doctors, laboratory professionals and genetic counselors about what is happening right now in genetics and genomics; and view the latest products available in the extensive exhibit hall.

Topics range from common conditions to rare diseases. Sessions include information of interest to the general public, to health professionals and to the industry/trade.

The ACMG Meeting is the genetics meeting most focused on the practical applications of genetic discoveries in a clinical setting.

###

To see the complete program, visit http://www.acmgmeeting.net.

Photo/TV Opportunity: The ACMG Foundation will present bicycles to local children with rare genetic diseases at the Annual Day of Caring at the Annual Meeting in Phoenix.

To receive a complimentary media registration, contact Kathy Ridgely Beal, MBA at kbeal@acmg.net for the Press Registration Access Code.

Read more here:
ACMG 2013 Clinical Genetics Meeting -- Complimentary press registration is now open

Recommendation and review posted by Bethany Smith

BOCA RATON, FL--(Marketwire - Jan 14, 2013) - Atossa Genetics ( NASDAQ : ATOS ), the Breast Health Company, based in Seattle, Washington, and Clarity Women's Health (a division of Diagnostic Test Group, LLC) of Boca Raton, Florida, announced today the launch of the ForeCYTE Breast Health Test at Clarity's national sales meeting, held on January 10-11th, 2013, in Boca Raton, Florida. The patented ForeCYTE Breast Health Test is designed for the early detection of precancerous breast conditions and the determination of the future risk of breast cancer, using a clinically validated algorithm including family history, personal reproductive history and breast cytopathology. The ForeCYTE Test, which uses the patented, FDA-cleared MASCT Breast Health System to painlessly collect a tiny sample of nipple ductal fluid, is designed to be performed at the point of care in a non-invasive and highly sensitive manner.

"Clarity Women's Health brings tremendous relationships with its clients driven by highly skilled technical support and customer service teams. I believe we have a strong national launch strategy working with the Clarity team and we anticipate rapid adoption as physicians' access to the ForeCYTE test is expanded," said Chris Destro, Vice President of Sales and Marketing, Atossa Genetics, Inc. "The passion and commitment of the entire team at Clarity Women's Health to make a difference in the current paradigm of breast health is palpable."

"The ForeCYTE Breast Health Test is the cornerstone of our new division, Clarity Women's Health," stated Daniel Lger, Vice President of Sales and Marketing, Diagnostic Test Group, LLC. "This product is targeted for over 110 million women between the ages of 18 and 73 in the U.S. who can now obtain a simple test in their physician's office and learn their future risk of breast cancer up to eight years before mammography can pick it up. This kind of advanced information was created for cervical cancer by the Pap smear and was responsible for the 75% reduction in the incidence of cervical cancer. The ForeCYTE Breast Health Test has the potential to do the same for breast cancer."

For more information, please click the following link to view a video interview with Christopher Destro, VP of Sales and Marketing of Atossa genetics discussing aspects of this press release in more detail: http://client.irwebkit.com/AtossaGenetics/media. You may also sign up to receive automatic email News Alert updates there.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

About Clarity Women's Health

Clarity Women's Health is a division of Diagnostic Test Group, LLC in Boca Raton, FL, and is a sales, marketing and branding company focused on the sale and distribution of its own Clarity brand of rapid and diagnostic tests, molecular tests, and diagnostic equipment utilized in physicians' offices, clinics, labs, urgent care centers and hospitals. DTG offers one of the largest lines of diagnostic tests in the industry supported by its own national sales force combined with in-house 24 hour customer service and tech support. Clarity products are available at most of the recognized national distributors. The ForeCYTE Breast Health System will form the cornerstone of its newly created division, Clarity Women's Health.

Original post:
Atossa Genetics and Clarity Women's Health Announce U.S. Launch of the ForeCYTE Breast Health Test

Recommendation and review posted by Bethany Smith

C5 Incomplete Spinal Cord Injury: 6 months post and taking steps

By: taccettaable

Excerpt from:
C5 Incomplete Spinal Cord Injury: 6 months post and taking steps - Video

Recommendation and review posted by sam

Breaking Through the CSPG Roadblock. Spinal Cord Injury in Nepal.
Drs. Ravi Bellamkonda and Jerry Silver, along with Nepalese PT Damodar Thapa, in a Question and Answer session following their presentations.

By: unite2fightparalysis

Continued here:
Breaking Through the CSPG Roadblock. Spinal Cord Injury in Nepal. - Video

Recommendation and review posted by sam

"Regenerating Functions that Mediate Motor Function after Spinal Cord Injury" - Dr. Oswald Steward
Dr. Steward discusses the discovery and progress of pTen deletion and related therapies.

By: unite2fightparalysis

Read more:
"Regenerating Functions that Mediate Motor Function after Spinal Cord Injury" - Dr. Oswald Steward - Video

Recommendation and review posted by sam

Genetic engineering human-animal genetic hybrid or chimera
Genetic engineering human-animal genetic hybrid or chimera Trans-Humanism Mixing Human DNA with Animal DNA. Tom Horn WARNING of disaster BREAKING NEWS ALERT WARNING TO HUMAN RACE human-animal genetic hybrid or chimeras full grown thousands of labs worldwide with animal human experiments this is sick and funded by the world Governments. Do your research what the UN is preparing to do between now and 2025 worldwide. We are in the end times last days the medical field is playing god DANGEREOUS times we are living Part Human part animal genetic hybrids A parahuman or para-human is a human-animal Genetic engineering human-animal genetic hybrid or chimera hybrid or chimera. Scientists have done extensive research into the mixing of genes or cells from different species, eg adding human (and other animal) genes to bacteria and farm animals to mass-produce insulin and spider silk proteins, and introducing human cells into mouse embryos. Parahumans have been referred to as "human-animal hybrids" in a vernacular sense that also encompasses human-animal chimeras. The term parahuman is not used in scientific publications. The term is sometimes used to sensationalize research that involves mixing biological materials from humans and other species. It was used in a National Geographic article to describe an experiment in 2003, during which Chinese scientists at the Shanghai Second Medical University successfully fused human cells with rabbit eggs. According to Daily Mail, as of 2011 ...

By: u2bheavenbound

Follow this link:
Genetic engineering human-animal genetic hybrid or chimera - Video

Recommendation and review posted by Bethany Smith

The Youth Pill
Science for the Public, September 10, 2010. David Stipp, author of The Youth Pill: Scientists at the Brink of an Anti-Aging Revolution. discusses how scientific and medical researchers are addressing the issue of aging. As modern populations live longer, it is necessary to understand both the aging process itself and the potential for greater longevity with good health. Mr. Stipp makes a sharp distinction between bogus claims of an easy way to obtain longevity and the very serious research in genetics and other fields suggesting the possibility of extending productive life. He offers a very clear analysis of the scientific data on aging, and he argues the case for more research and better public information on this issue.

By: scienceforpublic

View post:
The Youth Pill - Video

Recommendation and review posted by Bethany Smith

Minecraft Lets Play - Episode 25 - MINECRAFT COW GENETICS GONE WRONG
Please leave a like! It helps out a lot! 🙂 Minecraft, The game where cows have sex and pop out a horrible genetically wrong cow.. Enjoy!! 😀 Facebook Page: http://www.facebook.com

By: JJGaming000

See more here:
Minecraft Lets Play - Episode 25 - MINECRAFT COW GENETICS GONE WRONG - Video

Recommendation and review posted by Bethany Smith

Sentinels training 2012JAN11 [uncut]
ETHOS outfit ( ethosoutfit.forumsmotion.com ) Shortcuts: 11:20 mdash; Briefing 22:05 mdash; Mission #1 (Aurora materials lab) 26:50 mdash; Mission #2 (Apex genetics) 36:25 mdash; Mission #3 (Saerro listening post) 49:26 mdash; Side mission (C @ Saerro listening post) 58:00 mdash; Mission #4 (Palos solar array) 59:23 mdash; Tank push 1:03:00 mdash; Lib push 1:13:13 mdash; Mission #5 (Spec-ops training camp) 1:19:38 mdash; Mission #6 (Lost end outlook) 1:26:40 mdash; Mission #7 (Red ridge communications) 1:43:20 mdash; Training summary 1:48:35 mdash; ROBOCaster #39;discussion #39;

By: #1040; #1083; #1077; #1082; #1089; #1077; #1081; #1050; #1080; #1088; #1100; #1103; #1085; #1086; #1074;

See the rest here:
Sentinels training 2012JAN11 [uncut] - Video

Recommendation and review posted by Bethany Smith

Published: 1/12/2013 3:25 PM | Last update: 1/12/2013 11:53 PM By Ken Stephens - The Hutchinson News - kstephens@hutchnews.com AgReliant Genetics finalized contracts last week for a corn breeding research facility and nursery near Mount Hope, Harlan Priddle, executive director of the K-96 Corridor Development Association announced at the organization's annual meeting Friday.

AgReliant Genetics, headquartered in Indiana, has purchased and will remodel two metal buildings just south of K-96 and two miles west of Mount Hope for the seed research station. Mike Popelka, the station manager and corn breeder, said construction work would begin within the month and hopefully be finished in March.

Initially the facility will employ Popelka and Bryan Unruh, the yield trial manager. Full-time employment is expected to grow to three or four people over the next couple of years, but AgReliant also will employ about 25 part-time seasonal workers to help with hand-pollinating the corn and other tasks, Popelka said.

The research station will develop new hybrid varieties of yellow No. 2 corn to be grown in the western corn belt of Kansas, southern Nebraska, southwest Iowa and western Missouri, Popelka said. The No. 2 corn is used primarily for cattle feed.

In a press release, AgReliant said the southwest section of the corn belt has been a key source of growth for the company and the goal of the station would be to continue the development of top-performing hybrids for irrigated and dry land farming.

The seed research station will be one of 11 operated by AgReliant in North America but the first in Kansas. AgReliant's other research stations are in Nebraska, Iowa, Minnesota, Illinois, Indiana, Michigan and Ontario, Canada.

In recent weeks the company obtained a special use permit from Reno County for the research station. But there were details that still needed to be ironed out before AgReliant was ready to confirm its plans in Reno County.

Popelka received a Bachelor of Science degree from Kansas State University and doctorate in plant breeding from Purdue University. Unruh received his Master of Science degree in crop production from Kansas State.

Reno County Commission Chairman James Schlickau, a member of the K-96 association's board of directors, said he was excited that the seed research station was coming to southwest Reno County.

"I think it's a great use of the land and buildings out there," he said.

See the original post here:
Corn genetics facility coming to Mount Hope

Recommendation and review posted by Bethany Smith

gene therapy strategies to offensive biowarfare
source-thayer.dartmouth.edu

By: jon clem

Read the original here:
gene therapy strategies to offensive biowarfare - Video

Recommendation and review posted by Bethany Smith

Big Data and Predictive Analytics for Personalized Medicine
entelos.com Tom Paterson, CTO of Entelos, discusses hypothesis management in drug discovery and how to use Entelos biosimulation software for a different take on big data and predictive analytics for personalized medicine. This is part of the webinar Tom presented on December 12, 2012.

By: Entelossolutions

See the rest here:
Big Data and Predictive Analytics for Personalized Medicine - Video

Recommendation and review posted by sam

Stem Cell Treatment Spinal Cord Injury D12
He has history of accident 3 months back, leading to fracture D12 vertebra with loss of bowel bladder control. He was then operated for spinal stabilization. He has not been rehabilitated. Neurologically, he is hypotonic and hyporeflexic. On examination: he has grade 0 muscle power in bilateral lower extremities and near normal upper extremities. He has sensory loss below T12 level. He has no bowel bladder control and has been on indwelling catheter. He has very poor sitting balance. Functionally, he is completely dependent for all ADL and wheelchair bound for mobility. Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com After Stem Cell Therapy Clinical Improvements seen After Neuro Regenerative Rehabilitation Therapy (NRRT). 1. Overall stamina improved. 2. His spasticity has reduced in right leg. 3. He can now do independently supine to sit. Earlier, he was totally dependent. 4. Earlier, he used to take support of two persons to turn supine to sidelying. Now, he himself makes efforts and need one person #39;s assistance and 50% less support. 5. His sitting balance while at bed edge long sitting has improved. a. His sitting balance with backrest has improved.Earlier,he could hardly sit without discomfort, for10-15 minutes. Now, he can sit for without discomfort for 30 ...

By: neurogenbsi

More:
Stem Cell Treatment Spinal Cord Injury D12 - Video

Recommendation and review posted by sam

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dd7jnv/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering.

Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Companies Mentioned

Follow this link:
Research and Markets: Stem Cell Therapy Market in Asia-Pacific to 2018

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/t5whmr/cardiovascular) has announced the addition of Jain PharmaBiotech's new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" to their offering.

Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.

Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimize the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system. Devices for drug delivery to the cardiovascular system are also described.

Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions.A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.Fifteen companies are involved in drug-eluting stents.

The cardiovascular drug delivery markets are estimated for the years 2011 to 2021 on the basis of epidemiology and total markets for cardiovascular therapeutics. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.

Selected 80 companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 78 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 27 tables and 7 figures.

Key Topics Covered:

Executive Summary

See the article here:
Research and Markets: Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cvngvs/cytogenetics) has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering.

This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies.

FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described.

Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects.

The chapter on markets provides a global perspective of the cytogenetics business in the major markets: US, Western Europe (including France, Germany, Italy, Spain, and the UK), and Japan. The total figures for the market are also broken out according to the technologies and major disease areas in which they are applied. Markets figure are given for the year 2012 and estimates are made for the years 2017 and 2022. Advantages and limitations of various technologies have been pointed out throughout the report but this chapter includes SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis of some of the competing technologies including the following: conventional FISH, innovative FISH technologies, PCR-based assays, and single molecule imaging. Unfulfilled needs in cytogenetics market are depicted graphically. Among various technologies, FISH is most advanced and less opportunities for further development than single molecule detection, which is in infancy and has more future potential.

The report includes summary profiles of 70 companies relevant to cytogenetics along with their 68 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified.The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography.

Key Topics Covered:

Executive Summary

1. Introduction

Read this article:
Research and Markets: Cytogenetics - Technologies, Markets and Companies - 2013

Recommendation and review posted by Bethany Smith